Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
“Heparin monitoring remains one of the most challenging areas in laboratory hemostasis.
While chromogenic Anti-Xa assays are increasingly the gold standard over aPTT due to their superior specificity and reduced interference, a critical question often goes overlooked in clinical practice.
Are we truly capturing the patient’s physiological heparin status, or are we just seeing the effect of our reagent selection?
From the impact of Dextran Sulfate (DXS) causing artifactual dissociation of heparin complexes, to the critical nature of PF4-mediated neutralization during pre-analytical phases, the way we measure is as vital as the numerical result itself.
With the ISTH 2026 Congress in Paris just a week away, heparin monitoring is taking center stage. Several sessions in the upcoming program are dedicated to this exact topic, highlighting how analytical variables directly influence clinical decision-making and patient safety in high-stakes environments like cardiac surgery and critical care.
In the carousel below, we break down:
- Why assay choice matters (The ‘DXS’ variable).
- How to master pre-analytical variables to avoid underestimation.
- Current 2024–2026 best practices from ISTH, BSH, and SFH guidelines.
Reliable monitoring requires more than just measuring activity—it requires a deep understanding of how that activity is being measured.
Are you attending ISTH 2026? Let’s connect and discuss the future of hemostasis monitoring.”
Find more posts featuring Bruno Pougault on Hemostasis Today.
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:12Rethinking Stroke Prevention – New Frontiers in Minimizing Bleeding Concerns – ISTH
-
Jul 4, 2026, 14:40Liver Cirrhosis and Portal Vein Thrombosis: Understanding a Critical Complication
-
Jul 4, 2026, 14:40Debra Bellon: A Milestone for Global Rare Disease Advocacy in Nairobi
-
Jul 4, 2026, 14:11Erica Wood: Next Webinar from the Optimal Centre of Research Excellence on Improving Immunoglobulin Use
-
Jul 4, 2026, 14:07Ariela Marshall: Optimizing Inpatient Hematology Consult Services Through Best Practices And Strategy
-
Jul 4, 2026, 13:53Azusa Nagao: Why Is von Willebrand Disease Still Being Missed in Japan?